A test for covid-19 developed at the Center for Discovery and Innovation (CDI) of Hackensack Meridian Health, New Jersey’s largest health network, has been licensed to T2 Biosystems, Lexington, Mass. Wider deployment of the covid-19 test, already in use in the Hackensack Meridian Health network, will meet a crucial need amid the continuing spread of the novel coronavirus.
“Our scientists at CDI have given our health network a crucial tool to treat New Jersey patients in real time,” says Robert C. Garrett, FACHE, chief executive officer of Hackensack Meridian Health. “Now their innovation will help others at this time of urgent need.”
Under the agreement, T2 Biosystems is authorized to adapt the CDI-developed covid-19 test to the T2 Biosystems platform, and to market and distribute the test in places of need amid the expanding pandemic. The test will be capable of running on the T2Dx instrument. CDI’s diagnostic tool has been in use since March 12 under FDA’s policy on diagnostic tests for coronavirus disease-2019, and has significantly shortened the timeline for covid-19 testing in the Hackensack Meridian Health network.
“The test, a highly sensitive and accurate novel assay, provides definitive results quickly. It combines in a new format the best elements found in the CDC and WHO diagnostics,” says David S. Perlin, PhD, chief scientific officer and senior vice president of CDI. “The CDI scientists who worked tirelessly on this rapid test should be commended for moving fast to use their expertise to save lives.”
For more information, visit Hackensack Meridian Health’s CDI and T2 Biosystems.
Featured image: The T2Dx instrument from T2 Biosystems.
